CD46, CD46 molecule, 4179

N. diseases: 258; N. variants: 21
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Ki-1+ Anaplastic Large Cell Lymphoma
0.010 Biomarker disease BEFREE Favorable outcomes and reduced toxicity with a novel vinblastine-based non-high dose methotrexate (HDMTX) regimen (modified MCP-842) in pediatric anaplastic large cell lymphoma (ALCL): experience from India. 31774004 2020
Childhood Anaplastic Large Cell Lymphoma
0.010 Biomarker disease BEFREE Favorable outcomes and reduced toxicity with a novel vinblastine-based non-high dose methotrexate (HDMTX) regimen (modified MCP-842) in pediatric anaplastic large cell lymphoma (ALCL): experience from India. 31774004 2020
CUI: C3266262
Disease: Multiple Chronic Conditions
Multiple Chronic Conditions
0.010 Biomarker disease BEFREE Multiplex CRISPR/Cas9 gene editing and somatic cell nuclear transfer were used to generate pigs carrying functional knockouts of GGTA1, CMAH, B4GALNT2 and SLA class I. Fibroblasts derived from one- to four-fold knockout animals, and from multi-transgenic cells (human CD46, CD55, CD59, HO1 and A20) with the four-fold knockout were used to examine the effects on human IgG and IgM binding or complement activation in vitro. 31591751 2020
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.010 Biomarker disease BEFREE In median comparison among groups, subclinical atherosclerosis showed higher serum concentrations of MCP-1and lower serum concentrations of FGF-21. 31152776 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.010 Biomarker disease BEFREE In median comparison among groups, subclinical atherosclerosis showed higher serum concentrations of MCP-1and lower serum concentrations of FGF-21. 31152776 2019
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis
0.010 Biomarker disease BEFREE The transcriptional expression in peripheral white blood cells (WBCs) of CD46 and CD55 was investigated in 157 patients enrolled by the Validation of the Oxford Classification of IgAN group, looking for correlations with clinical and pathology features and estimated glomerular filtration rate (eGFR) modifications from renal biopsy to sampling. 29635535 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.010 Biomarker disease BEFREE <b>Methods:</b> Rabbits were divided into sham, heart failure (model), MCP, and perindopril groups, respectively. 30967790 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.010 Biomarker disease BEFREE <b>Methods:</b> Rabbits were divided into sham, heart failure (model), MCP, and perindopril groups, respectively. 30967790 2019
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia
0.010 GeneticVariation disease BEFREE A total of 96 children with ALL undergoing therapy with MCP-841 protocol were screened for all the ten exons of TPMT, exon 2, exon 3 and intron 2 of ITPA using bidirectional sequencing. 30806759 2019
CUI: C0039103
Disease: Synovitis
Synovitis
0.010 Biomarker disease BEFREE MCP joints with more severe synovitis ('bad joints') demonstrated significantly lower dGEMRIC values compared to MCP joints with less severe synovitis ('good joints') at time-points 0 and 3 months (p=0.002; p=0.019, respectively). 29998824 2019
CUI: C0039730
Disease: Thalassemia
Thalassemia
0.010 GeneticVariation group BEFREE HDAd5/35++ vectors for in vivo gene therapy of thalassemia had a unique capsid that targeted primitive HSPCs through human CD46, a relatively safe SB100X transposase-based integration machinery, a micro-LCR-driven γ-globin gene, and an MGMT(P140K) system that allowed for increasing the therapeutic effect by short-term treatment with low-dose O6-benzylguanine plus bis-chloroethylnitrosourea. 30422819 2019
CUI: C0085409
Disease: Polyendocrinopathies, Autoimmune
Polyendocrinopathies, Autoimmune
0.010 Biomarker group BEFREE We found that placental DAF and CD46 decreased in β2GPI passively immunized APS model mice, accompanied by C3 deposition, neutrophil infiltration and increased proinflammatory cytokine levels detected in its placenta. 31091357 2019
CUI: C0270736
Disease: Essential Tremor
Essential Tremor
0.010 Biomarker disease BEFREE Significant atrophy of bilateral MCP and ICP and bilateral cerebellar GM was observed in ET. 31161314 2019
CUI: C0271979
Disease: Thalassemia Intermedia
Thalassemia Intermedia
0.010 Biomarker disease BEFREE We showed in "healthy" human CD46-transgenic mice and in a mouse model of thalassemia intermedia that our in vivo approach resulted in stable γ-globin expression in the majority of circulating red blood cells. 30422819 2019
CUI: C0275544
Disease: Congenital infectious disease
Congenital infectious disease
0.010 Biomarker group BEFREE Further, we demonstrate a CD46-dependent entry pathway of virus infection in trophoblasts, but not in fibroblasts, highlighting the complexity of CMV entry and identifying CD46 as an entry factor in congenital infection. 31221976 2019
CUI: C0742038
Disease: Cerebellar signs
Cerebellar signs
0.010 Biomarker phenotype BEFREE This study aims to evaluate the macrostructural integrity of the superior, middle, and inferior cerebellar peduncles (SCP, MCP, ICP) and cerebellar gray and white matter (GM, WM) volumes in patients with ET, and compare these volumes between patients with and without cerebellar signs (ETc and ETnc). 31161314 2019
CUI: C0751606
Disease: Adult Acute Lymphocytic Leukemia
Adult Acute Lymphocytic Leukemia
0.010 GeneticVariation disease BEFREE A total of 96 children with ALL undergoing therapy with MCP-841 protocol were screened for all the ten exons of TPMT, exon 2, exon 3 and intron 2 of ITPA using bidirectional sequencing. 30806759 2019
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.010 Biomarker group BEFREE Thus, CD46 is an excellent target for antibody-based therapy development, which has potential to be applicable to both adenocarcinoma and neuroendocrine types of mCRPC that are resistant to current treatment. 30185663 2018
CUI: C0004096
Disease: Asthma
Asthma
0.010 Biomarker disease BEFREE CD46 induced autophagy and decreased the oxidative stress-mediated apoptosis of respiratory epithelium, and this may offer a new therapeutic strategy to treat asthma. 30154478 2018
CUI: C0010054
Disease: Coronary Arteriosclerosis
Coronary Arteriosclerosis
0.010 Biomarker disease BEFREE Aberrant histone modifications of global histone and <i>MCP-1</i> promoter in CD14<sup>+</sup> monocytes from patients with coronary artery disease. 29609686 2018
CUI: C0010068
Disease: Coronary heart disease
Coronary heart disease
0.010 Biomarker disease BEFREE Aberrant histone modifications of global histone and <i>MCP-1</i> promoter in CD14<sup>+</sup> monocytes from patients with coronary artery disease. 29609686 2018
CUI: C0015302
Disease: External exotoses
External exotoses
0.010 Biomarker disease BEFREE Dorsal erosions [odds ratio (OR) 4.0], osteophytes (OR 2.1) and extensor tendinitis (OR 4.6) increased the risk of underestimating inflammation of MCP and PIP joints and osteophytes (OR 3.0) also increased the risk of overestimating inflammation. 29471516 2018
CUI: C0017152
Disease: Gastritis
Gastritis
0.010 Biomarker disease BEFREE Our study results suggested that the prophylactic administration of MCP reduced ethanol-induced gastric injury in rats through the suppression of gastric inflammation and oxidative stress, predominantly via NF-κB inhibition. 29307809 2018
CUI: C0022821
Disease: Kyphosis deformity of spine
Kyphosis deformity of spine
0.010 GeneticVariation phenotype BEFREE Focusing on the expression of the major Bicoid target, hunchback (hb), at the onset of zygotic transcription, we used the MS2-MCP approach which combines fluorescent labeling of nascent mRNA with live imaging at high spatial and temporal resolution. 30365533 2018
CUI: C0030389
Disease: Parainfluenza
Parainfluenza
0.010 Biomarker disease BEFREE Many viruses incorporate cellular regulators of complement activation (RCA) to block complement pathways and our prior work has shown that Parainfluenza virus 5 (PIV5) incorporates CD55 and CD46 to delay complement-mediated neutralization. 29693588 2018